Patients with recurrent primary (IDH-wild type), high-grade glioma were enrolled in a phase I study and treated with LMF (NCT01891747; patient characteristics, Table 1, first column LMF + bevacizumab + temozolomide). This evidence concerns the gene IDH1 and central nervous system cancer.